Holen Sie sich die Stockscreener-App
0.3719
0.50%
-0.0044
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Context Therapeutics Begins Phase I Trial of Bispecific Antibody in Nectin-4-Positive Tumors - GenomeWeb
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 - marketscreener.com
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid Tumors - quiverquant.com
A cancer treatment enters human testing for three cancers - Stock Titan
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
CNTX Stock Price, Quote & Chart - ChartMill
Context Therapeutics (CNTX) Edges Up 1.56% as Stock Holds Above $0.37 SupportRisk Reward Setups - vinanet.vn
Context Therapeutics Inc. Revenue Breakdown – NASDAQ:CNTX - TradingView
Context (CNTX) Quarterly Figures: EPS Comes in Below Forecast for This Review; Post-Earnings: Shares Fall 1.81% - vinanet.vn
Enterprise value to EBITDA forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
a2026mar-contextxcorpdec.htm - SEC.gov
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Context Therapeutics Inc. (CNTX) Stock Price, News, Quote & History - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Context Therapeutics (CNTX) Slips 6.6% to $0.45, Pressing Key Support at $0.43Factor Rotation - dars.gov.et
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
LifeSci Capital Maintains Context Therapeutics(CNTX.US) With Hold Rating, Announces Target Price $2 - Moomoo
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context drops bispecific T-cell engager on cost-cutting initiative - finance.yahoo.com
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics advancing CT-202 into clinic in Australia - BioWorld News
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - TradingView
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - marketbeat.com
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
CNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingView
Context Therapeutics (CNTX) Advances 2.93% as Biotech Tests Key $0.65 Resistance ZoneMonthly Profile - vinanet.vn
Weekly Recap: CNTX Nasdaq notice and Q2 2026 $0.09 loss forecast - TradingView
Enterprise value to revenue forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics Inc. Receives Nasdaq Delisting Notice – Form 8-K Filing Details and Company Response - Minichart
Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Context Therapeutics (CNTX): Octagon group reports 3.3% beneficial stake in Schedule 13G/A - Stock Titan
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - TipRanks
Context Therapeutics (CNTX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
Context Therapeutics (CNTX) Tests Key Support Level After 4.37% DeclineTick Index - vinanet.vn
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – FWB:6K9 - TradingView
CNTX|Context Therapeutics Inc|Price:0.603|Chg%:+0.003 - TradingKey
BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX) - Stock Titan
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
Context Therapeutics Inc (CNTX) Balance Sheet - TradingKey
Context Therapeutics Inc (CNTX) Income Statement - TradingKey
Context Therapeutics Inc (CNTX) Cash Flow - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Earnings Date & Reports & Earnings News - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – SWB:6K9 - TradingView
Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX - TradingView
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):